151 related articles for article (PubMed ID: 31536652)
1. Treatment and clinical outcomes in anti-p200 pemphigoid: a systematic review.
Laufer Britva R; Amber KT; Cohen AD; Kridin K
J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):465-472. PubMed ID: 31536652
[TBL] [Abstract][Full Text] [Related]
2. Coexistence of Anti-p200 Pemphigoid and Psoriasis: A Systematic Review.
Xie YH; Wang SH; Li SZ; Zuo YG
Front Immunol; 2022; 13():839094. PubMed ID: 35317170
[TBL] [Abstract][Full Text] [Related]
3. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
Raffin D; Delaplace M; Roussel A; Estève E
Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
[TBL] [Abstract][Full Text] [Related]
4. Anti-p200 Pemphigoid: A Systematic Review.
Kridin K; Ahmed AR
Front Immunol; 2019; 10():2466. PubMed ID: 31695695
[TBL] [Abstract][Full Text] [Related]
5. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid.
Kasperkiewicz M; Hoppe U; Zillikens D; Schmidt E
Clin Exp Dermatol; 2010 Aug; 35(6):614-7. PubMed ID: 19874345
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunological features and outcome of anti-p200 pemphigoid.
Commin MH; Schmidt E; Duvert-Lehembre S; Lasek A; Morice C; Estival JL; Debarbieux S; Rigal E; Pauwels C; De Quatrebarbes J; Roussel A; Goujon E; Stoebner PE; Jouen F; Joly P
Br J Dermatol; 2016 Oct; 175(4):776-81. PubMed ID: 27037896
[TBL] [Abstract][Full Text] [Related]
7. [Anti-p200 pemphigoid: a spectacular response to dapsone].
Munsch C; Prey S; Joly P; Meyer N; Lamant L; Livideanu C; Viraben R; Paul C
Ann Dermatol Venereol; 2011 Nov; 138(11):739-42. PubMed ID: 22078034
[TBL] [Abstract][Full Text] [Related]
8. Anti-p200 pemphigoid: diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease.
Egan CA; Yee C; Zillikens D; Yancey KB
J Am Acad Dermatol; 2002 May; 46(5):786-9. PubMed ID: 12004326
[TBL] [Abstract][Full Text] [Related]
9. [Anti-p200 pemphigoid].
Holtsche MM; Goletz S; Zillikens D
Hautarzt; 2019 Apr; 70(4):271-276. PubMed ID: 30868255
[TBL] [Abstract][Full Text] [Related]
10. [Anti-p200 pemphigoid: clinical, diagnostic and therapeutic aspects].
Drerup KA; Wehkamp U
Hautarzt; 2020 Feb; 71(2):130-133. PubMed ID: 31501972
[TBL] [Abstract][Full Text] [Related]
11. Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.
Tsai YJ; Cho YT; Chu CY
Am J Clin Dermatol; 2022 Jul; 23(4):571-585. PubMed ID: 35579853
[TBL] [Abstract][Full Text] [Related]
12. Anti-p200 pemphigoid in a 17-year-old girl successfully treated with systemic corticosteroid and dapsone.
Yamane N; Sawamura D; Nishie W; Abe M; Kodama K; Adachi K; Nakamura H; Ishii N; Hashimoto T; Shimizu H
Br J Dermatol; 2007 May; 156(5):1075-8. PubMed ID: 17381449
[No Abstract] [Full Text] [Related]
13. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.
Bernard P; Reguiai Z; Tancrède-Bohin E; Cordel N; Plantin P; Pauwels C; Vaillant L; Grange F; Richard-Lallemand MA; Sassolas B; Roujeau JC; Lok C; Picard-Dahan C; Chosidow O; Vitry F; Joly P
Arch Dermatol; 2009 May; 145(5):537-42. PubMed ID: 19451497
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of Treatment Options and Clinical Outcomes in Pemphigoid Gestationis.
Genovese G; Derlino F; Cerri A; Moltrasio C; Muratori S; Berti E; Marzano AV
Front Med (Lausanne); 2020; 7():604945. PubMed ID: 33330568
[No Abstract] [Full Text] [Related]
15. Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption.
Hübner F; Kasperkiewicz M; Knuth-Rehr D; Shimanovich I; Hübner J; Süfke S; Muck P; Zillikens D; Schmidt E
J Dtsch Dermatol Ges; 2018 Sep; 16(9):1109-1118. PubMed ID: 30179319
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.
Oren-Shabtai M; Kremer N; Lapidoth M; Sharon E; Atzmony L; Nosrati A; Hodak E; Mimouni D; Levi A
Drugs Aging; 2021 Feb; 38(2):125-136. PubMed ID: 33230804
[TBL] [Abstract][Full Text] [Related]
17. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.
Meijer JM; Diercks GF; Schmidt E; Pas HH; Jonkman MF
JAMA Dermatol; 2016 Aug; 152(8):897-904. PubMed ID: 27167149
[TBL] [Abstract][Full Text] [Related]
18. Lack of predictive factors for the clinical course of bullous pemphigoid.
Venning VA; Wojnarowska F
J Am Acad Dermatol; 1992 Apr; 26(4):585-9. PubMed ID: 1597545
[TBL] [Abstract][Full Text] [Related]
19. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.
Dainichi T; Koga H; Tsuji T; Ishii N; Ohyama B; Ueda A; Natsuaki Y; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
J Dermatol; 2010 Mar; 37(3):231-8. PubMed ID: 20507386
[TBL] [Abstract][Full Text] [Related]
20. Management of bullous pemphigoid: recommendations for immunomodulatory treatments.
Kirtschig G; Khumalo NP
Am J Clin Dermatol; 2004; 5(5):319-26. PubMed ID: 15554733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
